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Background: The 70% methanol extract of Terminalia chebula Retz. fruit (TCME) was investigated for its in vitro iron
chelating property and in vivo ameliorating effect on hepatic injury of iron overloaded mice.
Methods: The effect of fruit extract on Fe2+-ferrozine complex formation and Fe2+ mediated pUC-18 DNA
breakdown was studied in order to find the in vitro iron chelating activity. Thirty-six Swiss Albino mice were divided
into six groups of: blank, patient control and treated with 50, 100, 200 mg/kg b.w. of TCME and desirox (standard
iron chelator drug with Deferasirox as parent compound). Evaluations were made for serum markers of hepatic
damage, antioxidant enzyme, lipid per oxidation and liver fibrosis levels. The reductive release of ferritin iron by
the extract was further studied.
Results: In vitro results showed considerable iron chelation with IC50 of 27.19± 2.80 μg/ml, and a significant DNA
protection with [P]50 of 1.07 ± 0.03 μg/ml along with about 86% retention of supercoiled DNA. Iron-dextran
injection (i.p.) caused significant increase in the levels of the serum enzymes, viz., alanine aminotransferase (ALAT),
aspartate aminotransferase (ASAT), alkaline phosphatase (ALP) and Bilirubin, which were subsequently lowered
by oral administration of 200 mg/kg b.w. dose of the fruit extract by 81.5%, 105.88%, 188.08% and 128.31%,
respectively. Similarly, treatment with the same dose of the extract was shown to alleviate the reduced levels of
liver antioxidant enzyme superoxide dismutase, catalase, glutathione S-transferase and non-enzymatic reduced
glutathione, by 49.8%, 53.5%, 35.4% and 11% respectively, in comparison to the iron overloaded mice. At the same
time, the fruit extract effectively lowered the iron-overload induced raised levels of lipid per oxidation, protein
carbonyl, hydroxyproline and liver iron by 49%, 67%, 67% and 26%, respectively, with oral treatment of 200 mg/kg
b.w. dose of TCME. The fruit extract also showed potential activity for reductive release of ferritin iron.
Conclusions: These findings suggest that Terminalia chebula extract may contain active substances capable of
lessening iron overload induced toxicity, and hence possibly be useful as iron chelating drug for iron overload
diseases.Background
Iron is an important trace element of the body, being
found in functional form in hemoglobin, myoglobin, the
cytochromes, enzymes with iron sulphur complexes and
other iron-dependent enzymes [1]. Iron has the unique
ability to alter its oxidation and redox states in response
to liganding, which makes it essential for various cellular
processes [2]. The cells maintain the free iron concentra-
tion to a minimum required level to avoid toxic effects* Correspondence: mandaln@rediffmail.com
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reproduction in any medium, provided the orof excess iron. But, in some situation the iron balance is
disrupted and resulting in iron overload which is asso-
ciated with the oxidative stress induced several health
problems including anemias, heart failure, liver cirrhosis,
fibrosis, gallbladder disorders, diabetes, arthritis, depres-
sion, impotence, infertility, and cancer [3]. The body
lacks any effective means to excrete excessive iron and
therefore the interest has been grown to develop the
potent chelating agent capable of complexing with iron
and promoting its excretion [4,5].
Terminalia chebula Retz. (abbreviated as TC) from
Combretaceae family is an important medicinal herbtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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parts of the world [6]. The dried ripe fruit of TC is used
widely in the indigenous system of medicine (ayurvedic)
for its homeostatic, antitussive, laxative, diuretic, and
cardiotonic activities [7] and serves as a major compo-
nent of widely used ayurvedic formulation, ‘Triphala’ [8].
TC extract has also been reported to exhibit a variety
of biological activities including antioxidant [9-11], anti-
cancer [12-14], cytoprotective [15], antidiabetic [16,17],
antibacterial [18], gastro protective [19] and hepatopro-
tective [20] activities. The phytochemical analysis shows
that TC is a rich source of various phenolic and flavon-
oid compounds [21] which are well known for their free
radical scavenging and iron chelation property [22]. Earl-
ier, we have also reported the ROS scavenging and redu-
cing property of 70% methanol extract of T. chebula and
it also found to possess significant amount of phenolic
and flavonoid compounds [23].
Iron overload increases the formation of reactive
oxygen species (ROS) which involves the initiation of
lipid peroxidation, protein oxidation and liver fibrosis.
However, excess iron is stored as Fe3+ in ferritin and
iron overload sustains for long period if the stored iron
is not getting reduced and released because the effi-
ciency of iron chelating drugs depend on the reductive
release of ferritin iron [24]. Moreover, 70% methanol
extract of T. chebula was earlier reported to contain
some notable antioxidants, viz., ellagic acid, 2,4-chebulyl-
β-D-glucopyranose and chebulinic acid [12]. Based on
these observations, the present study was performed to
assess iron chelating activity of 70% methanol extract of
T. chebula (TCME) and whether this activity along with
reducing power can normalize the damage caused to
liver by iron overload.
Methods
Chemicals
Iron-dextran and guanidine hydrochloride was pur-
chased from Sigma-Aldrich, USA. Trichloroacetic acid
(TCA), nitro blue tetrazolium (NBT), reduced nicotinamide
adenine dinucleotide (NADH), phenazine methosulfate
(PMS), ferrozine, glutathione reduced, bathophenanthroline
sulfonate disodium salt, thiobarbituric acid (TBA), and
5,5′-dithiobis-2-nitrobenzoic acid (DTNB) were obtained
from Sisco Research Laboratories Pvt. Ltd, Mumbai, India.
Hydrogen peroxide, ammonium iron (II) sulfate hexahy-
drate [(NH4)2Fe(SO4)26H2O], 1-chloro-2,4-dinitrobenzene
(CDNB), chloramine-T, hydroxylamine hydrochloride,
dimethyl-4-aminobenzaldehyde and 2,4-dinitro phenyl-
hydrazin (DNPH) were obtained from Merck, Mumbai,
India. Ferritin was purchased from MP Biomedicals,
USA. Streptomycin sulphate was obtained from HiMedia
Laboratories Pvt. Ltd, Mumbai, India. The standard oral
iron chelating drug, desirox, with the parent groupDeferasirox, was obtained from Cipla Ltd., Kolkata,
India.
Plant material
The fruits of TC were collected from Bankura district of
West Bengal, India. It was identified and authenticated
by the Central Research Institute (Ayurveda), Kolkata,
India and a voucher specimen (CRHS 113/08) was sub-
mitted there.
Animals
Male Swiss albino mice (20± 2 g) were purchased from
Chittaranjan National Cancer Institute (CNCI), Kolkata,
India and were maintained under a constant 12 h dark/
light cycle at an environmental temperature of 22 ± 2°C.
The animals were provided with normal laboratory pellet
diet and water ad libitum. All experiments were per-
formed after obtaining approval from the Institutional
Animal Ethics Committee, with certified regulations of
the Committee for the Purpose of Control and Supervi-
sion of Experiments on Animals (CPCSEA), Ministry of
Environment and Forest, Govt. of India (Bose Institute
Registration. No. 95/1999/CPCSEA).
Preparation of plant extract
The powder (100 g) of the air dried fruits of TC was
stirred using a magnetic stirrer with 500 ml mixture of
methanol: water (7:3) for 15 h; then the mixture was
centrifuged at 2850 x g and the supernatant decanted.
The process was repeated again with the precipitated
pellet. The supernatants were collected, concentrated in
a rotary evaporator and lyophilized. The dried extract,
denoted as TCME was stored at −20°C until use. An
aqueous solution with various concentrations of TCME
was used for all the experiments.
In vitro study
Iron chelation
The chelating activity of TCME for ferrous ion was eval-
uated by a previously described method [25]. In a Hepes
buffer (20 mM, pH 7.2) medium, TCME (0–120 μg/ml)
was added to ferrous sulfate solution (12.5 μM) and the
reaction was started by the addition of ferrozine
(75 μM). The mixture was shaken vigorously and left
standing for 20 min at room temperature. The absorb-
ance was then taken at 562 nm. All tests were performed
six times. EDTA was used as a positive control.
DNA protection
The DNA protection was studied using supercoiled
pUC18 plasmid DNA according to an earlier reported
method [26], with minor modifications. In Hepes buffer
(pH 7.2, 100 mM), FeSO4 solution (750 μM), TCME of
varying doses (0–5 μg/ml), DNA (0.5 mg/ml) and water
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H2O2 solution (7.5 mM) was added to start the reaction.
After 10 min, the reaction was terminated by adding
Desferal as stopping reagent followed by loading buffer.
25 μl of each reaction mixture was loaded in 1% agarose
gel. After migration, the gel was stained with ethidium
bromide and visualized in a UV transilluminator. The
DNA bands were quantified through densitometry and
the following formulae were used to calculate the per-
centage of protection.
%SC ¼ 1:4 SC= OC þ 1:4 SCð Þð Þ½   100
where, SC = supercoiled; OC= open circular; 1.4 = cor-
rection factor
%protection ¼ 100 controlSC  chelatorSCð Þ½
= controlSC  nochelatorSCð Þ  1
The ability of the fruit extract to protect the DNA
supercoil can be expressed by the concentration of




Thirty-six mice were distributed into six groups com-
prising six mice in each group. One group received nor-
mal saline only and served as blank (B). The other five
groups were given five doses (one dose every two days)
of 100 mg/kg b.w. each, of iron-dextran saline (i.p). Nor-
mal saline was administered to one iron-dextran group
(C) and other four groups were orally treated with
50 mg/kg b.w. (S50), 100 mg/kg b.w. (S100), 200 mg/kg
b.w. (S200) TCME and 20 mg/kg b.w. desirox (D),
respectively, for three consecutive 7 day periods, started
from the day after the first iron-dextran injection.
Sample collection and tissue preparation
Mice were fasted overnight after the experiment ended
on the 21st day. Then they were anesthetized by ethyl
ether and blood was collected by cardiac puncture. After
the clotting of blood samples, sera were separated by
centrifugation and stored at −80°C until analysis. The
liver was dissected out and blood cells were eliminated
after rinsing with ice-cold saline, half of them were cut,
weighed and homogenized in 10 volume of 0.1 M phos-
phate buffer (pH 7.4) containing 5 mM EDTA and
0.15 M NaCl, and centrifuged at 8000 x g for 30 min at
4°C. The supernatant was collected and used for the
determination of lipid per oxidation, protein oxidation,
hydroxyproline content and enzyme activities. A stand-
ard graph of BSA was prepared to estimate the protein
concentration in the homogenate by Lowry method [27].
The other half of the liver samples were weighed anddigested with equivolume (1:1) mixture of sulphuric acid
and nitric acid and their iron content were analysed.
Serum enzymes
Alanine aminotransferase (ALAT), aspartate aminotrans-
ferase (ASAT) and bilirubin in serum samples were mea-
sured using the commercial kits of Merck, Mumbai,
India. Alkaline phosphatase (ALP) was estimated using
the kit supplied by Sentinel Diagnostics, Italy.
Antioxidant enzymes
Superoxide dismutase (SOD) was assayed by measuring
the inhibition of the formation of blue colored formazan
at 560 nm according to the technique reported previ-
ously [28]. Catalase (CAT) activity was measured by fol-
lowing the decomposition of H2O2 over time at 240 nm
according to a previously described method [29].
Glutathione-S-transferase (GST) was determined by a
formerly reported method [30] based on the formation
of GSH-CDNB conjugate and increase in the absorbance
at 340 nm. Reduced glutathione (GSH) level was mea-
sured spectrophotometrically at 412 nm by a standard
method [31].
Lipid peroxidation products
According to a formerly reported method [32], the lipid
peroxide levels in liver homogenates were measured
in terms of thiobarbituric acid reactive substances
(TBARS), as an index of malondialdehyde accumulation.
Protein carbonyl content
As a marker of protein oxidation, protein carbonyl con-
tents were estimated spectrophotometrically by a previ-
ously described method [33]. Briefly, 450 μl sample
homogenate was mixed with 50 μl streptomycin sulphate
(10% w/v) and then centrifuged at 2800 g for 15 min.
Then 200 μl of the supernatant was incubated with the
same volume of 10 mM DNPH in 2 M HCl at room
temperature for 20 min. After the reaction was com-
pleted, 10% cold TCA was added to precipitate the pro-
teins and the precipitates were washed with ethyl
acetate-ethanol mixture (1:1) for three times to remove
unreacted DNPH. The final protein pellet was dissolved
in 1 ml of 6 M guanidine hydrochloride solution and the
absorbance was measured at 370 nm, using the molar
extinction coefficient of DNPH, ε= 2.2x10-4 M-1 cm-1.
Hydroxyproline content
Hydroxyproline content represents the content of colla-
gen, which is closely related with liver fibrosis. Liver
samples were hydrolized in 6 M HCl and hydroxyproline
was measured by Ehrlich’s solution according to the
method described previously [34]. A standard curve
(R2= 0.9907) of 4-hydroxy-L-proline was prepared and
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558 nm. The collagen content was determined by multi-
plying amount of total hydroxyproline content in each
sample by a factor of 7.69 [35]. Results are expressed as
milligrams of collagen per liver (wet weight).Liver iron and serum ferritin
Liver iron was measured according to a formerly
reported colorimetric method [36]. Samples were incu-
bated with bathophenanthroline sulfonate for 30 min at
37 °C and absorbances were measured at 535 nm. Serum
ferritin levels were measured using enzyme-linked
immunosorbent assay kit (from Monobind Inc., USA)
according to the manufacturer’s instructions.Iron release from ferritin
Iron release assay was performed according to a previ-
ously described method [37]. The release of ferritin iron
was measured using the ferrous chelator ferrozine as a
chromophore. The reaction mixture (3 ml final volume)
contained 200 μg ferritin, 500 μM ferrozine, in 50 mM
pH 7.0 phosphate buffer. Reaction was started by the
addition of 500 μl TCME of different concentrations
(100–500 μg) and the change in absorbance was mea-
sured continuously at 560 nm for 20 min. A cuvette
containing ferritin, ferrozine and phosphate buffer but
lacking plant extract was used as the reference solution.Statistical analysis
All data are reported as the mean ± SD of six measure-
ments. Statistical analysis was performed using KyPlot
version 2.0 beta 15 (32 bit) and Origin professional 6.0.
Comparisons among groups were made according
to pair t-test. The IC50 values were calculated by the for-
mula, Y = 100*A1/(X +A1) where A1 = IC50, Y = response
(Y= 100% when X=0), X= inhibitory concentration. In all
analyses, a p value of < 0.05 was considered significant.Figure 1 In vitro iron chelating activity. Effect of (a) TCME and (b) standa
% inhibition of chromogen formation. The results are mean± S.D. of six paResults
In vitro study
Ferrozine makes a violet colored complex with Fe2+ ion.
The complex formation is interrupted in presence of
chelating agent and as a result the violet color of the
complex is decreased. The results [Figures 1(a) and 1(b)]
demonstrated that the formation of ferrozine-Fe2+ com-
plex is inhibited in the presence of TCME and reference
compound EDTA. The IC50 values of the TCME and
EDTA were 27.19± 2.80 μg/ml and 1.27± 0.05 μg/ml,
respectively. At 120 μg/ml, 69% of the percentage of
inhibition of complex formation by the TCME was found.
The protective effect of TCME against Fe2+-H2O2 me-
diated DNA breakdown was demonstrated in Figure 2(a).
pUC18 supercoiled DNA was used as control (lane 1).
The treatment of supercoiled DNA with Fenton’s re-
agent led to the conversion of DNA to open circular
form (lane 2). The addition of different concentrations
of TCME resulted in the restoration of DNA in the
supercoiled form (lane 3–12). The results in Figure 2(b)
showed the dose dependant protective effect of TCME
with a [P]50 value of 1.07 ± 0.03 μg/ml.In vivo study
Serum enzymes
Iron induced liver injury resulted in the significant
increase in the levels of ALAT, ASAT, ALP and bilirubin.
As shown in Table 1, oral administration of TCME
in S200 group markedly reduced the levels of ALAT
by 81.5%, ASAT by 105.88%, ALP by188.08%; and bili-
rubin by 128.31%, whereas a reduction of 74.29%,
83.55%, 185.04% and 124.87% was found in the standard
desirox treated group for ALAT, ASAT, ALP and bili-
rubin, respectively.Antioxidant enzymes
The activities of antioxidant enzymes SOD, CAT, GST
and the levels of non-enzymic antioxidant GSH were
significantly decreased in iron overloaded control micerd EDTA on ferrozine-Fe2+ complex formation. The data expressed as
rallel measurements. ***p< 0.001 vs 0 μg/ml.
Figure 2 Inhibition of DNA damage. Protection against oxidative damage to pUC18 by TCME. Picture of agarose gel of pUC18 DNA
showing bands of supercoiled (SC) and open circular (OC) forms. Lanes on the gel represent: (Lane 1) control DNA (no H2O2 or Fe
2+); (Lane 2)
reaction mixture without extract; (Lane 3–12) reaction mixture with extract of increasing concentration (0.5-5 μg/ml). **p< 0.01 and
***p< 0.001 vs 0 μg/ml.
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SOD activity observed in the test control compared with
normal group, was successively reduced to 6.4%, 24%
and 39.8% following the feeding of S50, S100 and S200
respectively (Figure 3); and to 32.9% upon treatment
with standard desirox. The activity of CAT was shown
in Figure 4. The overload of iron in liver resulted in 72%
decrease in CAT activity compared to non-iron over-
loaded normal mice. But 40.4%, 41.3% and 53.5% reduc-
tion was observed; when the iron intoxicated mice were
fed 50, 100 and 200 mg/kg b.w. of TCME respectively,
which approached the value for desirox (61.5%). GST ac-
tivity was reduced 73.2% in iron treated control mice.
But after the treatment with 50, 100 and 200 mg/kg b.w.
of TCME, the activity was enhanced 3.7%, 22.8% and
35.4% respectively (Figure 5), the last being better than
30.3% reduction achieved by the reference desirox. The
activity of GSH was significantly reduced (31%) in iron
intoxicated control mice. The GSH levels in S50, S100Table 1 The effect of TCME on serum marker enzymes (ALAT,
Treatment ALAT ASAT
Unit/L % Change Unit/L % Chan
B 16.87 ± 2.07 — 30.07 ± 1.77 —
C 36.08 ± 2.76X2 113.79 69.8 ± 1.46X3 132.1
S50 33.27 ± 2.91X2 97.12 50.67 ± 3.58X2Y2 68.5
S100 30.85 ± 2.53X2 82.75 43.71 ± 1.33X2Y3 45.3
S200 22.33 ± 1.99X1Y1 32.29 37.96 ± 2.13X2Y3 26.2
D 23.55 ± 1.39X1Y1 39.54 44.67 ± 5.52X1Y1 48.5
Values are mean ± SD of six observations.
X: significant difference from normal mice (B) group (X1: p≤ 0.05, X2: p≤ 0.01 and X
Y: significant difference from iron overloaded (C) group (Y1: p≤ 0.05, Y2: p ≤ 0.01 anand S200 groups increased about 3%, 5% and 11%, re-
spectively (Figure 6), comparable to the activity of
desirox (9.6%).
Lipid peroxidation
The intraperitoneal injection of iron-dextran signifi-
cantly enhanced (67%) lipid peroxidation in liver homo-
genates compared to normal control mice. However, the
levels of TBARS were markedly reduced to 5%, 40% and
49% in groups S50, S100 and S200 respectively (Figure 7),
whereas standard desirox generated 44.2% decrease.
Protein carbonyl content
Oxidative modification of proteins is another conse-
quence of iron overload induced toxicity and carbonyl
formation may be an early marker for protein oxidation.
A significant elevation (197%) of protein carbonyl con-
tent in iron overloaded mice was found to be arrested
by 20%, 42% and 67% in S50, S100 and S200 groupASAT and ALP) and Bilirubin in iron overloaded mice
ALP Bilirubin
ge Unit/L % Change Unit/L % Change
133.58 ± 7.76 — 1.29 ± 0.15 —
3 398.76 ± 24.73X2 198.51 3.21 ± 0.23X3 147.88
1 265.11 ± 19.09X2Y3 98.45 2.45 ± 0.19X3Y2 88.89
5 236.08 ± 12.25X2Y2 76.73 1.92 ± 0.19X2Y3 48.41
5 147.52 ± 12.11Y2 10.43 1.55 ± 0.06X1Y2 19.57
8 151.58 ± 9.92X2Y2 13.47 1.59 ± 0.12X2Y2 23.01
3: p≤ 0.001).
d Y3: p≤ 0.001).
Figure 3 Increase in SOD level. Effect of TCME on the SOD levels
against iron overload induced hepatic injury in mice. Mice were
randomly divided into six groups (blank, B; control, C; 50 mg/kg b.w.
TCME, S50; 100 mg/kg b.w. TCME, S100; 200 mg/kg b.w. TCME, S200;
desirox group, D) and treated as described in ‘experimental design’
section. Values are expressed as mean± SD of six mice. ***p≤ 0.001
compared with blank and ###p≤ 0.001 compared with control.
Figure 5 Effect on GST level. Effect of TCME on the GST levels
against iron overload induced hepatic injury in mice. Mice were
randomly divided into six groups (blank, B; control, C; 50 mg/kg b.w.
TCME, S50; 100 mg/kg b.w. TCME, S100; 200 mg/kg b.w. TCME, S200;
desirox group, D) and treated as described in ‘experimental design’
section. Values are expressed as mean± SD of six mice. **p≤ 0.01,
***p≤ 0.001 compared with blank and ##p≤ 0.01, ###p≤ 0.001
compared with control.
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parison to 67% as found for desirox treated group.Hydroxyproline content
The hydroxyproline content was determined as it signi-
fies the enhanced level of collagen content in liver fibro-
sis. As shown in Figure 9, 77% increase of collagen
content in iron overloaded mice compared to normal
mice was reduced to 5%, 29% and 67% in TCME treated
mice (S50, S100 and S200 respectively); and 43% in
D group.Figure 4 Elevation of Catalase activity. Effect of TCME on the CAT
levels in iron overload induced hepatic damage in mice. Mice were
randomly divided into six groups (blank, B; control, C; 50 mg/kg b.w.
TCME, S50; 100 mg/kg b.w. TCME, S100; 200 mg/kg b.w. TCME, S200;
desirox group, D) and treated as described in ‘experimental design’
section. Values are expressed as mean± SD (n = 6). **p≤ 0.01,
***p≤ 0.001 compared with blank and ###p≤ 0.001 compared
with control.Liver iron and serum ferritin
Liver iron content was elevated about 124% after intra-
peritoneal administration injection of iron dextran. The
TCME treatment (S50, S100 and S200) evidently low-
ered the iron content at a level of 7%, 17% and 26%
respectively (Figure 10), although not quite as good
as desirox treatment that lowered by 68%. Significant in-
crease (165%) of serum ferritin level in iron loaded mice
was substantially reduced to 92%, 111% and 161% as
treated with TCME dose dependently to S50, S100 andFigure 6 Increment of GSH activity. Effect of TCME on the GSH
levels against iron overload induced hepatic damage in mice.
Mice were randomly divided into six groups (blank, B; control, C;
50 mg/kg b.w. TCME, S50; 100 mg/kg b.w. TCME, S100; 200 mg/kg
b.w. TCME, S200; desirox group, D) and treated as described in
‘experimental design’ section. Values are expressed as mean± SD of
six mice. ***p≤ 0.001 compared with blank and #p≤ 0.05,
###p≤ 0.001 compared with control.
Figure 7 Inhibition of lipid peroxidation. Hepatic lipid
peroxidation levels in different treated mouse liver. Mice were
randomly divided into six groups (blank, B; control, C; 50 mg/kg b.w.
TCME, S50; 100 mg/kg b.w. TCME, S100; 200 mg/kg b.w. TCME, S200;
desirox group, D) and treated as described in ‘experimental design’
section. Values are expressed as mean± SD of six mice. *p≤ 0.05,
**p≤ 0.01, ***p≤ 0.001 compared with blank and #p≤ 0.05,
###p≤ 0.001 compared with control.
Figure 9 Effect on collagen content. Collagen content in different
treated mouse liver. Mice were randomly divided into six groups
(blank, B; control, C; 50 mg/kg b.w. TCME, S50; 100 mg/kg b.w.
TCME, S100; 200 mg/kg b.w. TCME, S200; desirox group, D) and
treated as described in ‘experimental design’ section. Values are
expressed as mean± SD (n= 6). ***p≤ 0.001 compared with blank
and #p≤ 0.05, ##p≤ 0.01, ###p≤ 0.001 compared with control.
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than that of the desirox group with reduction of 138%.
Iron release from ferritin
The ability of TCME to release iron from ferritin
was tested using ferrous chelator ferrozine as a chro-
mophore. Ferrozine formed a complex with ferrous ion,
[Fe(ferrozine)3]
2+, which was quantified to measure the
reductive release of ferritin iron. The time course for the
reaction is depicted in Figure 12. Control experimentsFigure 8 Effect on protein oxidation. Inhibitory effect of TCME
on protein oxidation levels in iron overloaded mice. Mice were
randomly divided into six groups (blank, B; control, C; 50 mg/kg b.w.
TCME, S50; 100 mg/kg b.w. TCME, S100; 200 mg/kg b.w. TCME, S200;
desirox group, D) and treated as described in ‘experimental design’
section. Protein carbonyl content was assayed to measure the extent
of protein oxidation. Values are expressed as mean± SD (n = 6).
***p≤ 0.001 compared with blank and #p≤ 0.05, ###p≤ 0.001
compared with control.devoid of TCME produced negligible percent of released
iron, whereas, after dose dependant (100–500 μg)
addition of TCME, significant amount of iron (45%-63%)
was released within 20 minutes.
Correlation between reducing power with ferritin
iron release
In the present study, the correlation between reducing
power and released ferritin iron (%) by TCME was ana-
lyzed. The correlation graph is depicted in Figure 13.
Results showed a positive correlation coefficient (R =
0.9318) between the reducing power and the amount ofFigure 10 Hepatic iron content regulation. Effect of TCME on
hepatic iron content in different treated mouse liver. Mice were
randomly divided into six groups (blank, B; control, C; 50 mg/kg b.w.
TCME, S50; 100 mg/kg b.w. TCME, S100; 200 mg/kg b.w. TCME, S200;
desirox group, D) and treated as described in ‘experimental design’
section. Values are expressed as mean± SD of six mice. ***p≤ 0.001
compared with blank and ##p≤ 0.01, ###p≤ 0.001 compared
with control.
Figure 11 Decrease of serum ferritin level. Serum ferritin levels in
different treated mouse. Mice were randomly divided into six groups
(blank, B; control, C; 50 mg/kg b.w. TCME, S50; 100 mg/kg b.w.
TCME, S100; 200 mg/kg b.w. TCME, S200; desirox group, D) and
treated as described in ‘experimental design’ section. Values are
expressed as mean± SD of six mice. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001
compared with blank and ##p≤ 0.01, ###p≤ 0.001 compared
with control.
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(p < 0.001).
Discussion
Iron is the most common cofactor within the oxygen
handling biological machinery and, specifically, lipid per-
oxidation of biological membranes is the main patho-
genic mechanism of iron overload induced tissue
damage [38]. Harmful effects of extreme iron deposition
in liver are likely during iron overload states (e.g., gen-
etic hemochromatosis, thalassemia major and transfu-
sional siderosis). In such conditions, iron has been
associated with the initiation and propagation of ROS
induced oxidative damage to all biomacromoleculesFigure 12 Release of ferritin iron. Dose dependent formation of the [Fe(
with time. The reductive release of ferritin iron was quantified by measurin
at 562 nm using a Shimadzu UV–VIS spectrophotometer.(proteins, lipids, sugar and DNA) that can lead to a crit-
ical failure of biological functions and ultimately cell
death [39]. An effective therapeutic approach can play a
double role in reducing the rate of oxidation - one by
sequestering and chelating cellular iron stores [40] and
other as radical trap (i.e., antioxidant activity). Since
TCME has shown antioxidant and free radical scaven-
ging activity [24], the present study, primarily incorpo-
rates the in vitro iron chelation potency of TCME, and
inhibition of iron mediated DNA breakdown. Conse-
quently, in vivo ameliorating effect of TCME on iron
accumulation and oxidative damage in liver of iron over-
loaded mice is studied. Intraperitoneal iron-dextran
injection resembled the hemochromatosis secondary to
iron loaded anemias (anemias treated with repeated
transfusions) and high iron oral intake [41], while avoid-
ing direct interruption of fruit extract on intestinal iron
absorption leading to hepatic and serum iron overload.
Intracellular defense mechanism against free radical
generation and pathogenesis involves antioxidant enzymes
such as SOD, CAT, GST or compounds such as GSH
[42]. Excess iron imbalances their levels with excess ROS
production thus resulting oxidative stress, followed by
peroxidative decomposition of cellular membrane lipids
which is a postulated mechanism of hepatocellular injury
in iron overload [43]. Alongside, the iron overload gener-
ated ROS can lead to oxidation of protein backbone
resulting in modification of catalytic and structural integ-
rity of various important proteins [44] contributing to the
pathogenesis of liver fibrosis [45]. In turn, hepatic injury
by iron results in the leakage of cellular enzymes into the
bloodstream, resulting in augmented levels of serum
ALAT, ASAT, ALP and bilirubin [1].
The in vitro results from Figure 1 suggest that TCME
has iron chelating activity, although not as good as theferrozine)3]
2+ complex following release of Fe2+ from ferritin by TCME
g the formation of the ferrous complex of ferrozine, [Fe(ferrozine)3]
2+
Figure 13 Correlation of ferritin iron release and reducing power. Correlation of reducing power versus release of ferritin iron (%) by TCME.
Sarkar et al. BMC Complementary and Alternative Medicine 2012, 12:144 Page 9 of 10
http://www.biomedcentral.com/1472-6882/12/144standard EDTA. The significant dose-dependent reduc-
tion in the formation of Fe2+-dependent hydroxyl radical
induced nicked DNA and increase in supercoiled DNA
in the presence of TCME reveal its excellent iron chelat-
ing activity. The in vivo results showed that TCME
administration in iron overloaded mice restored the anti-
oxidant enzymes level significantly. Chiefly, the present
study demonstrated the lipid peroxidation and protein
oxidation inhibiting capability of TCME, which is sup-
posed to be associated with its iron chelating activity.
Iron overload causes a significant increase of hydroxy-
proline, a marker of liver fibrosis. Treatment with TCME
significantly reduced hydroxyproline content in iron
intoxicated mice, thus demonstrating the hepatic fibrosis
inhibitory potency of the fruit extract. Moreover, the
direct effect of TCME to reduce hepatic iron content in
treated mice supported its iron chelating potency. Above
all, TCME reduced the serum enzymes as well as the
total Bilirubin levels, indicating its protective effect over
liver damage by iron overload and improvement in its
functional efficiency.
Ferritin is a ubiquitous intracellular protein that stores
iron in a non-toxic ferric form and also helps prevent
iron from mediating oxidative damage to cell constitu-
ents [46]. Serum ferritin concentration is the most sensi-
tive indicator of the severity of iron overload and its
level usually increases when body’s iron stores increase.
In this study, the ferritin level was found enhanced in
iron overloaded mice, whereas, the level significantly
reduced after the treatment with TCME.
Maximum iron chelators depend on the availability
of Fe2+, which in turn depends on the rate of reductive
release of iron from ferritin. Therefore, successive chela-
tion therapy includes the supplementation of ascorbate
as reducing agent to increase the availability of storage
iron to chelators [47]. Previously, TCME had shownreductive ability [24] as well as in the present study; a
significant positive correlation between reducing power
and iron released from ferritin has been well established.
Therefore, TCME can also be used as drug to treat
iron overload as the present results show its reductive
release activity of ferritin iron dose dependently as well
as time dependently.
Conclusions
The current investigation of 70% methanolic extract of
Terminalia chebula showed that the extract which pos-
sesses both reducing power and iron chelating activity
can reduce the toxic level of iron in iron overloaded
mice and hence protect liver from oxidative stress and
fibrosis. Taken together, the current findings will be of
use in elucidating the pharmacology and application
of TCME as a potential iron chelating drug in the treat-
ment of iron overload diseases.
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